On or around 06/02/2017 (Ongoing date of last review)
Filing Date: June 02, 2017
According to a law firm press release, pursuant to the terms of the Merger Agreement, Fresenius will acquire all of the outstanding shares of Akorn common stock for $34.00 per share in cash.
On May 22, 2017, the Company filed a proxy statement (the “Proxy Statement”) with the United States Securities and Exchange Commission (“SEC”) in connection with the Proposed Transaction. According to the Complaint, the Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement false and misleading.
Company & Securities Information
Defendant: Akorn, Inc.
Industry: Major Drugs
Headquarters: United States
Ticker Symbol: AKRX
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Robert Berg , et al. v. Akorn, Inc., et al.
COURT: M.D. Louisiana
DOCKET #: 17-CV-00350
JUDGE: Hon. Brian A. Jackson
DATE FILED: 06/02/2017
CLASS PERIOD START: 04/24/2017
CLASS PERIOD END: 06/02/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
O'Bell, L.L.C. 3500 North Hullen Street, O'Bell, L.L.C., LA 70002 504.456.8600 504.456.8653 ·